Floatz logo

Anti-Cd19/Cd22 Car-T Cells

Acute Lymphobkastic Leukemia

Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyCell therapyPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Acute Lymphobkastic Leukemia cohort.

Asset / SponsorPhaseRating
Shb-02-Cd19
Sheba Medical Center
Phase 1/2CCC

Same molecule, other indications

Anti-Cd19/Cd22 Car-T Cells is also rated in:

Auto Stem Cell TransplantDormant
B
Indicative ·
57 / 100
View asset →
CAR T Cell TherapyDormant
B
Indicative ·
57 / 100
View asset →
Large B-cell LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →